オハイオにおける統合失調症の臨床試験
オハイオ内の拠点で、統合失調症に関する18件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
- Vanda Investigational Site, Cincinnati
- Vanda Investigational Site, Garfield Heights
- Vanda Investigational Site, Westlake
被験者募集中第4相
12歳〜17歳 · 全性別 · 2026/10/01更新 · NCT05648591Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Westlake Brain Health, Westlake
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/30更新 · NCT07101094Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Local Institution - 0183, Cincinnati
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/09/28更新 · NCT07686263NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Sites, North Canton
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/09/25更新 · NCT07114874NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, North Canton
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/09/25更新 · NCT07105098Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- University of Cincinnati Medical Center, Cincinnati
- Charak Center for Health and Wellness, Garfield Heights
被験者募集中第3相
5歳〜17歳 · 全性別 · 2026/09/25更新 · NCT06229210A Study of Brenipatide in Adult Participants With Schizophrenia
- Insight Clinical Trials, Independence
被験者募集中第2相
18歳〜55歳 · 全性別 · 2026/09/22更新 · NCT07410507A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- University of Cincinnati Cancer Institute, Cincinnati
- Local Institution - 0148, Cincinnati
被験者募集中第3相
5歳〜17歳 · 全性別 · 2026/09/22更新 · NCT07424404A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Independence
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/18更新 · NCT0710511152-week Open Label Safety-Tolerability Study
- Neuro-Behavioral Clinical Research, Canton
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/09/09更新 · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- University of Cincinnati Dept of Psychiatry and Behavioral Neuroscience, Cincinnati
被験者募集中第3相
13歳〜17歳 · 全性別 · 2026/09/04更新 · NCT07288567A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, North Canton
- Clinical Site, West Chester
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/09/01更新 · NCT07459647Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Local Institution - 0031, Mason
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/19更新 · NCT07379827REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)
- Case Western Reserve University, Cleveland
被験者募集中
18歳〜50歳 · 全性別 · 2026/08/17更新 · NCT07006935Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Alkermes Investigator Site, Cincinnati
- Alkermes Investigator Site, West Chester
被験者募集中第3相
10歳〜17歳 · 全性別 · 2026/08/14更新 · NCT05303064Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
- Neuro-Behavioral Clinical Research, North Canton
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/07/27更新 · NCT07363577A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Neuro-Behavioral Clinical Research, North Canton
被験者募集中第2相
18歳〜55歳 · 全性別 · 2026/06/23更新 · NCT07191483Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
- Harding Hospital, Columbus
被験者募集中
15歳〜35歳 · 全性別 · 2026/02/25更新 · NCT04368039ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。